Inicio › Linfoma folicular › Massachusetts › Boston
Ensayos clínicos de Linfoma folicular en Boston, MA
17 estudios para Linfoma folicular buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
ReclutandoFase 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
ReclutandoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
ReclutandoFase 3
- Research Site, Boston
- Research Site, Boston
NEO100 and High-Grade Meningioma
ReclutandoFase 2
- Tufts Medical Center, Boston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
ReclutandoFase 3
- Beth Israel Deaconess Medical Center, Boston
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
ReclutandoFase 3
- Tufts Medical Center, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
ReclutandoFase 3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Epcoritamab and Rituximab for First-line Follicular Lymphoma
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
ReclutandoFase 3
- Local Institution - 0145, Boston
- Local Institution - 0244, Boston
- Local Institution - 0247, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
ReclutandoFase 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
ReclutandoFase 2
- Beth Israel Deaconess Medical Center, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ensayos de Linfoma folicular en otras ciudades
- New York City, NY24 estudios
- Milwaukee, WI19 estudios
- Nashville, TN18 estudios
- Houston, TX18 estudios
- Baldwin Park, CA16 estudios
- Seattle, WA16 estudios
- Durham, NC15 estudios
- Columbus, OH14 estudios
- Salt Lake City, UT12 estudios
- Philadelphia, PA12 estudios
- San Antonio, TX12 estudios
- Chicago, IL12 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer de pulmón de células no pequeñas89 estudios
- Cáncer (todos los tipos)86 estudios
- Cáncer del colon y del recto63 estudios
- Cáncer metastásico63 estudios
- Cáncer de pulmón62 estudios
- Cáncer de ovario61 estudios
- Cáncer de próstata60 estudios
- Depresión51 estudios
- Cáncer de endometrio50 estudios
- Leucemia mielógena aguda45 estudios
- Cáncer de páncreas44 estudios
De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.